Abstract

FORMULATION AND EVALUATION OF A MULTI-DRUG LOADED LIPOSOME FOR THE MANAGEMENT OF NON SMALL LUNG CANCER (NSLC)

Oyeniyi Y. J.*, Atata R. F. and Shuaibu B. A.

ABSTRACT

The physiochemical parameters As well as the cytotoxicity of novel liposomal formulations containing Osimertinib and Cetuximab were investigated in the management of non small cell lung cancer. The film hydration technique was use to produced batches of multidrug loaded liposomes which were thereafter characterized. The two cytotoxic drugs were loaded and entrapped successfully into the liposomes which were nano sized and spherically shaped. The entrapment efficiencies (EE) ranged 80.67±0.69 to 90.34± 1.49 indicating excellent polymer selection and formulations. The obtained EE ranking order was X_5 ≥ X_4 ≥ X_3 ≥ X_1 ≥ X_2. The batch to batch variations of assessed parameters were insignificant, (p≤ 0.05). The ranking for zeta potential (ZP), polydispersity index (PDI) and mean particle sizes (MPS) were X_5 ≤ X_4 ≤ X_3 ≤ X_1 ≤ X_2 ; X_5 = X_4 ≥ X_2 ≥ X_1 ≥ X_3 and X_5 ≥ X_4 ≥ X_2 ≥ X_3 ≥ X_1 respectively. The release profile of the two drugs monitored using a UV-Spectroscopy were gradual and in sustained manner for about 12 hours. The drug release data for the formulations were best fitted into Korsmeyer–Peppas mathematical model. The superior cell lethality of X_2 may be due to its high EE and CDR values. It’s our conclusion that the novel multi drug loaded liposomal formulations, X_1, 2 and 3 are suitable for scale up and pilot mass production after adequate process optimization. These multidrug loaded liposomal formulations will discourage poly pharmacy, reduce drug resistances resulting from non compliances and ultimately improve clinical management of NSCLC.

Keywords: Non small cell lung cancer, Osimertinib, Cetuximab and Liposomes.